Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Published:2016-11-28 Issue:12 Volume:68 Page:2857-2866
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Genovese Mark C.¹,Smolen Josef S.²,Weinblatt Michael E.³,Burmester Gerd R.⁴,Meerwein Sebastian⁵,Camp Heidi S.⁶,Wang Li⁶,Othman Ahmed A.⁶,Khan Nasser⁶,Pangan Aileen L.⁶,Jungerwirth Steven⁶

Affiliation:

1. Stanford University School of Medicine; Palo Alto California

2. Medical University of Vienna and Hietzing Hospital; Vienna Austria

3. Brigham and Women's Hospital; Boston Massachusetts

4. Charité-Universitätsmedizin Berlin; Berlin Germany

5. AbbVie Deutschland; Ludwigshafen Germany

6. AbbVie; North Chicago Illinois

Funder

AbbVie

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference31 articles.

1. The pathogenesis of rheumatoid arthritis;McInnes;N Engl J Med,2011

2. The JAK-STAT pathway at twenty;Stark;Immunity,2012

3. Janus kinase inhibitors in autoimmune diseases;O'Shea;Ann Rheum Dis,2013

4. Tofacitinib versus methotrexate in rheumatoid arthritis;Lee;N Engl J Med,2014

5. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial;Burmester;Lancet,2013

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities;Bioorganic & Medicinal Chemistry Letters;2024-09

2. Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital;Cureus;2024-08-25

3. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

4. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis;PLOS ONE;2024-07-31

5. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis;Modern Rheumatology;2024-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3